US2011218205A1PendingUtilityA1

Piperazine derivatives

49
Assignee: MS SCIENCE CORPPriority: Aug 9, 2005Filed: May 11, 2011Published: Sep 8, 2011
Est. expiryAug 9, 2025(expired)· nominal 20-yr term from priority
Inventors:Connie Sun
A61P 9/10A61P 43/00A61P 25/36A61P 25/16A61P 25/22A61P 25/20A61P 25/08A61P 25/14A61P 25/00A61P 27/02A61P 25/24A61P 25/18A61P 25/32A61P 25/28A61P 25/34A61P 25/04C07D 295/033A61P 21/02C07D 295/03C07D 317/58C07D 295/096A61P 21/00C07D 295/073
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compounds of general formula (I) A compound of general formula (I) in which— R 1 and R 0 have any of the meanings given in the specification have affinity for sigma receptors and are useful in the treatment of disorders of the central nervous system.

Claims

exact text as granted — not AI-modified
1 - 23 . (canceled) 
     
     
         24 . A method of treating a condition responsive to a modulator of sigma receptor function in a patient requiring treatment, which comprises administering to the patient an effective amount of a compound selected from 1-[2-(3,4,5-trimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine and pharmaceutically acceptable salts thereof. 
     
     
         25 - 31 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.